{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:50:06Z","timestamp":1790412606008,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clnesp.2023.08.028","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:52:02Z","timestamp":1693011122000},"page":"73-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-560X","authenticated-orcid":false,"given":"Valerie","family":"Taelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-874X","authenticated-orcid":false,"given":"Dimitri","family":"Declercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Van Biervliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick Vande","family":"Weygaerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1584-4965","authenticated-orcid":false,"given":"Bruno","family":"Lapauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-0747","authenticated-orcid":false,"given":"Eva","family":"Van Braeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clnesp.2023.08.028_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes"},{"issue":"10290","key":"10.1016\/j.clnesp.2023.08.028_bib2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"Suppl 2","key":"10.1016\/j.clnesp.2023.08.028_bib3","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jcf.2019.08.015","article-title":"Energy balance and obesity in individuals with cystic fibrosis","volume":"18","author":"Litvin","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"issue":"19","key":"10.1016\/j.clnesp.2023.08.028_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10212","key":"10.1016\/j.clnesp.2023.08.028_bib5","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.clnesp.2023.08.028_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.clnesp.2023.08.028_bib7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jand.2020.03.015","article-title":"Academy of nutrition and dietetics: 2020 cystic fibrosis evidence analysis center evidence-based nutrition practice guideline","volume":"121","author":"McDonald","year":"2021","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"6","key":"10.1016\/j.clnesp.2023.08.028_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MCP.0000000000000629","article-title":"Prevention of malnutrition in cystic fibrosis","volume":"25","author":"Slae","year":"2019","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.clnesp.2023.08.028_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen et\u00a0al","volume":"19","author":"Olesen","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.clnesp.2023.08.028_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines","year":"2021","journal-title":"J\u00a0Diabetes Complicat"},{"issue":"8","key":"10.1016\/j.clnesp.2023.08.028_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 2","key":"10.1016\/j.clnesp.2023.08.028_bib12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"issue":"10","key":"10.1016\/j.clnesp.2023.08.028_bib13","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.clnesp.2023.08.028_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"5","key":"10.1016\/j.clnesp.2023.08.028_bib15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jcf.2019.03.007","article-title":"The impact of cystic fibrosis-related diabetes on health-related quality of life","volume":"18","author":"Kwong","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.clnesp.2023.08.028_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jpeds.2012.08.040","article-title":"Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis","volume":"162","author":"Yen","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.clnesp.2023.08.028_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnesp.2023.08.028_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.clnesp.2023.08.028_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.clnesp.2023.08.028_bib20","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","author":"Petersen","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"7","key":"10.1016\/j.clnesp.2023.08.028_bib21","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J\u00a0Acad Nutr Diet 2021"},{"key":"10.1016\/j.clnesp.2023.08.028_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2020.111124","volume":"85","author":"King","year":"2021","journal-title":"Nutrition"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545772301224X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545772301224X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:46:48Z","timestamp":1719362808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545772301224X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":22,"alternative-id":["S240545772301224X"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2023.08.028","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2023.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}]}}